Molecular predictors of response and outcome in ovarian cancer

Critical Reviews in Oncology/Hematology

Volumn 60, Issue 1, 2006, Pages 19-37

  Canevari, Silvana ^a   Gariboldi, Manuela ^a,b   Reid, James F ^a,b   Bongarzone, Italia ^a   Pierotti, Marco A ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Omics technologies; Ovarian cancer; Prognostic factors

Indexed keywords

ABC TRANSPORTER; BIOLOGICAL MARKER; BRCA1 PROTEIN; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; GLYCOPROTEIN P; MOLECULAR MARKER; PLATINUM DERIVATIVE; PROTEIN P53; TAXANE DERIVATIVE;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; CODON; CROSS RESISTANCE; FUNCTIONAL PROTEOMICS; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; OVARY CANCER; PREDICTION; PROGNOSIS; RELAPSE; REVIEW; TREATMENT RESPONSE;

ALGORITHMS; FEMALE; GENOMICS; HUMANS; MODELS, BIOLOGICAL; OUTCOME ASSESSMENT (HEALTH CARE); OVARIAN NEOPLASMS; PROGNOSIS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 33748329519     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.03.003     Document Type: Review

References (214)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Cannistra S.A. Cancer of the ovary. N Engl J Med 351 (2004) 2519-2529
3. Ozols R.F., Bookman M.A., Connolly D.C., et al. Focus on epithelial ovarian cancer. Cancer Cell 5 (2004) 19-24
4. Ozols R.F., Schwartz P.E., and Eifel P.G. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: De Vita Jr., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 6th ed. (2004), Lippincott Williams & Wilkins, Phyladelphia 1597-1632
5. Berman M.L. Future directions in the surgical management of ovarian cancer. Gynecol Oncol 90 (2003) S33-S39
6. du Bois A, Quinn M, Thigpen,Vermorken JB, guest editors. Third International ovarian cancer consensus of the GCIG. Ann Oncol. 2005;16 (Suppl 8):1-42.
7. Harries M., and Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 3 (2002) 529-536
8. Vasey P.A. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 89 Suppl 3 (2003) S23-S28
9. Agarwal R., and Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3 (2003) 502-516
10. Ness R.B., and Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91 (1999) 1459-1467
11. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
12. Beachy P.A., Karhadkar S.S., and Berman D.M. Tissue repair and stem cell renewal in carcinogenesis. Nature 432 (2004) 324-331
13. Lahad J.P., Mills G.B., and Coombes K.R. Stem cell-ness: a "magic marker" for cancer. J Clin Invest 115 (2005) 1463-1467
14. Bell D.A. Origins and molecular pathology of ovarian cancer. Mod Pathol 18 Suppl 2 (2005) S19-S32
15. Shih I.-M., and Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164 (2004) 1511-1518
16. McShane L.M., Altman D.G., Sauerbrei W., et al. Reporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 41 (2005) 1690-1696
17. Bast Jr. R.C., Feeney M., Lazarus H., et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68 (1981) 1331-1337
18. Whitehouse C., and Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol Oncol 88 (2003) S152-S157
19. Fendrick J.L., Konishi I., Geary S.M., et al. CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line. Tumour Biol 18 (1997) 278-289
20. Rump A., Morikawa Y., Tanaka M., et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279 (2004) 9190-9198
21. Meyer T., and Rustin G.J. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 82 (2000) 1535-1538
22. Agarwal R., and Kaye S.B. Prognostic factors in ovarian cancer: how close are we to a complete picture?. Ann Oncol 16 (2005) 4-6
23. McGuire W.P. CA-125 and early ovarian cancer: does this help the clinician or further muddy the water?. J Clin Oncol 23 (2005) 5862-5864
24. Crawford S.M., and Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?. Ann Oncol 16 (2005) 47-50
25. Paramasivam S., Tripcony L., Crandon A., et al. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J Clin Oncol 23 (2005) 5938-5942
26. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., and Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 22 (2003) 7468-7485
27. Leslie E.M., Deeley R.G., and Cole S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204 (2005) 216-237
28. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., and Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51 (1991) 6304-6311
29. El-Deiry W.S. Regulation of p53 downstream genes. Semin Cancer Biol 8 (1998) 345-357
30. Zhao R., Gish K., Murphy M., et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 14 (2000) 981-993
31. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
32. Jenkins J.R., Rudge K., and Currie G.A. Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature 312 (1984) 651-654
33. Beroud C., and Soussi T. p53 gene mutation: software and database. Nucleic Acids Res 26 (1998) 200-204
34. Feki A., and Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 52 (2004) 103-116
35. Berchuck A., Kohler M.F., Marks J.R., et al. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 170 (1994) 246-252
36. Reles A., Wen W.H., Schmider A., et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7 (2001) 2984-2997
37. Johnstone R.W., Ruefli A.A., and Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
38. Kigawa J., Sato S., Shimada M., et al. p53 gene status and chemosensitivity in ovarian cancer. Hum Cell 14 (2001) 165-171
39. Schuyer M., van der Burg M.E., Henzen-Logmans S.C., et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 85 (2001) 1359-1367
40. Lavarino C., Pilotti S., Oggionni M., et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18 (2000) 3936-3945
41. Cimoli G., Malacarne D., Ponassi R., et al. Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs. Biochim Biophys Acta 1705 (2004) 103-120
42. Weinstein J.N., Myers T.G., O'Connor P.M., et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275 (1997) 343-349
43. Rose S.L., Robertson A.D., Goodheart M.J., et al. The impact of p53 protein core domain structural alteration on ovarian cancer survival. Clin Cancer Res 9 (2003) 4139-4144
44. Concin N., Becker K., Slade N., et al. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 64 (2004) 2449-2460
45. Shahin M.S., Hughes J.H., Sood A.K., and Buller R.E. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 89 (2000) 2006-2017
46. Fallows S., Price J., Atkinson R.J., et al. P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 194 (2001) 68-75
47. Risch H.A., McLaughlin J.R., Cole D.E., et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68 (2001) 700-710
48. Abeliovich D., Kaduri L., Lerer I., et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60 (1997) 505-514
49. Levy-Lahad E., Catane R., Eisenberg S., et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families [see comments]. Am. J. Hum. Genet. 60 (1997) 1059-1067
50. Moslehi R., Chu W., Karlan B., et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66 (2000) 1259-1272
51. Tutt A., and Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 8 (2002) 571-576
52. Wooster R., and Weber B.L. Breast and ovarian cancer. N Engl J Med 348 (2003) 2339-2347
53. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108 (2002) 171-182
54. Hartman A.R., and Ford J.M. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet 32 (2002) 180-184
55. Xu X., Weaver Z., Linke S.P., et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 3 (1999) 389-395
56. Rubin S.C., Benjamin I., Behbakht K., et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335 (1996) 1413-1416
57. Buller R.E., Shahin M.S., Geisler J.P., et al. Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res 8 (2002) 1196-1202
58. Boyd J., Sonoda Y., Federici M.G., et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283 (2000) 2260-2265
59. Ben-David Y., Chetrit A., Hirsh-Yechezkel G., et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20 (2002) 463-466
60. Cass I., Baldwin R.L., Varkey T., et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97 (2003) 2187-2195
61. Turner N., Tutt A., and Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4 (2004) 814-819
62. Hilton J.L., Geisler J.P., Rathe J.A., et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 94 (2002) 1396-1406
63. Taniguchi T., Tischkowitz M., Ameziane N., et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9 (2003) 568-574
64. Spinola P. Unravelling the genetics of complex disorders of reproduction. In: Countinho E.M. (Ed). Management of endometriosis (1999), The Parthenon Publishing Group, New York 284-287
65. Robert J., Morvan V.L., Smith D., Pourquier P., and Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 54 (2005) 171-196
66. Matlashewski G.J., Tuck S., Pim D., et al. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7 (1987) 961-963
67. Harris N., Brill E., Shohat O., et al. Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 6 (1986) 4650-4656
68. Thomas M., Kalita A., Labrecque S., et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19 (1999) 1092-1100
69. Baptiste N., Friedlander P., Chen X., and Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 21 (2002) 9-21
70. Dumont P., Leu J.I., Della III P.A., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33 (2003) 357-365
71. Bergamaschi D., Gasco M., Hiller L., et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3 (2003) 387-402
72. Wang Y., Kringen P., Kristensen G.B., et al. Effect of the codon 72 polymorphism (c.215G > C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 24 (2004) 21-34
73. Hogdall E.V., Hogdall C.K., Christensen L., et al. Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Anticancer Res 22 (2002) 1859-1864
74. Buller R.E., Sood A., Fullenkamp C., et al. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 4 (1997) 239-245
75. Agorastos T., Masouridou S., Lambropoulos A.F., et al. P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur J Cancer Prev 13 (2004) 277-280
76. Pegoraro R.J., Moodley M., Rom L., Chetty R., and Moodley J. P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans. Int J Gynecol Cancer 13 (2003) 444-449
77. Bange J., Prechtl D., Cheburkin Y., et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62 (2002) 840-847
78. Morimoto Y., Ozaki T., Ouchida M., et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98 (2003) 2245-2250
79. Streit S., Bange J., Fichtner A., et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 111 (2004) 213-217
80. Spinola M., Leoni V.P., Tanuma J., et al. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 14 (2005) 415-419
81. Spinola M., Leoni V., Pignatiello C., et al. The functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol (2005)
82. Stadler C.R., Knyazev P., Bange J., and Ullrich A. FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. Cell Signal (2005)
83. Sehouli J., Mustea A., Konsgen D., Katsares I., and Lichtenegger W. Polymorphism of IL-1 receptor antagonist gene: role in cancer. Anticancer Res 22 (2002) 3421-3424
84. Sehouli J., Mustea A., Koensgen D., and Lichtenegger W. Interleukin-1 receptor antagonist gene polymorphism in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 12 (2003) 1205-1208
85. Sehouli J., Mustea A., Koensgen D., Chen F.C., and Lichtenegger W. Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer. Ann Oncol 14 (2003) 1501-1504
86. Bojesen S.E., Tybjaerg-Hansen A., and Nordestgaard B.G. Integrin beta3 Leu33Pro homozygosity and risk of cancer. J Natl Cancer Inst 95 (2003) 1150-1157
87. Wang-Gohrke S., and Chang-Claude J. Re-integrin beta3 Leu33Pro homozygosity and risk of cancer. J Natl Cancer Inst 97 (2005) 778-779
88. Auranen A., Song H., Waterfall C., et al. Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer 117 (2005) 611-618
89. Bernardini M., Weberpals J., and Squire J.A. The use of cytogenetics in understanding ovarian cancer. Biomed Pharmacother 58 (2004) 17-23
90. Iwabuchi H., Sakamoto M., Sakunaga H., et al. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res 55 (1995) 6172-6180
91. Eder A.M., Sui X., Rosen D.G., et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci USA 102 (2005) 12519-12524
92. Arnold N., Hagele L., Walz L., et al. Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer. Genes Chromosomes Cancer 16 (1996) 46-54
93. Sonoda G., Palazzo J., du Manor S., et al. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer 20 (1997) 320-328
94. Patael-Karasik Y., Daniely M., Gotlieb W.H., et al. Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel. Cancer Genet Cytogenet 121 (2000) 26-32
95. Kudoh K., Takano M., Koshikawa T., et al. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. Clin Cancer Res 5 (1999) 2526-2531
96. Kallioniemi A., Kallioniemi O.P., Sudar D., et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258 (1992) 818-821
97. Launonen V., Mannermaa A., Stenback F., et al. Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables. Cancer Genet Cytogenet 122 (2000) 49-54
98. Dodson M.K., Hartmann L.C., Cliby W.A., et al. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res 53 (1993) 4456-4460
99. Liu Y., Heyman M., Wang Y., et al. Molecular analysis of the retinoblastoma gene in primary ovarian cancer cells. Int J Cancer 58 (1994) 663-667
100. Hogdall E.V., Ryan A., Kjaer S.K., et al. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study. Cancer 100 (2004) 2387-2395
101. Veldman T., Vignon C., Schrock E., Rowley J.D., and Ried T. Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping. Nat Genet 15 (1997) 406-410
102. Bayani J., Brenton J.D., Macgregor P.F., et al. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res 62 (2002) 3466-3476
103. Fishman A., Shalom-Paz E., Fejgin M., et al. Comparing the genetic changes detected in the primary and secondary tumor sites of ovarian cancer using comparative genomic hybridization. Int J Gynecol Cancer 15 (2005) 261-266
104. Umayahara K., Numa F., Inokuma A., et al. Genetic alterations related to lymph node metastasis and peritoneal dissemination in epithelial ovarian cancers. Oncol Rep 9 (2002) 1115-1119
105. Tapper J., Sarantaus L., Vahteristo P., et al. Genetic changes in inherited and sporadic ovarian carcinomas by comparative genomic hybridization: extensive similarity except for a difference at chromosome 2q24-q32. Cancer Res 58 (1998) 2715-2719
106. Brown R., and Strathdee G. Epigenomics and epigenetic therapy of cancer. Trends Mol Med 8 (2002) S43-S48
107. Toyota M., and Issa J.P. Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 32 (2005) 521-530
108. Balch C., Huang T.H., Brown R., and Nephew K.P. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 191 (2004) 1552-1572
109. Teodoridis J.M., Hall J., Marsh S., et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65 (2005) 8961-8967
110. Chan M.W., Wei S.H., Wen P., et al. Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res 11 (2005) 7376-7383
111. Strathdee G., Vass J.K., Oien K.A., et al. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol Oncol 97 (2005) 898-903
112. Hough C.D., Sherman-Baust C.A., Pizer E.S., et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 60 (2000) 6281-6287
113. Velculescu V.E., Zhang L., Vogelstein B., and Kinzler K.W. Serial analysis of gene expression. Science 270 (1995) 484-487
114. Auburn R.P., Kreil D.P., Meadows L.A., et al. Robotic spotting of cDNA and oligonucleotide microarrays. Trends Biotechnol 23 (2005) 374-379
115. Martoglio A.M., Tom B.D., Starkey M., et al. Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays. Mol Med 6 (2000) 750-765
116. Ismail R.S., Baldwin R.L., Fang J., et al. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res 60 (2000) 6744-6749
117. Wang K., Gan L., Jeffery E., et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 229 (1999) 101-108
118. Ono K., Tanaka T., Tsunoda T., et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60 (2000) 5007-5011
119. Sawiris G.P., Sherman-Baust C.A., Becker K.G., et al. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res 62 (2002) 2923-2928
120. Schummer M., Ng W.V., Bumgarner R.E., et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 238 (1999) 375-385
121. Matei D., Graeber T.G., Baldwin R.L., et al. Gene expression in epithelial ovarian carcinoma. Oncogene 21 (2002) 6289-6298
122. Brentani R.R., Carraro D.M., Verjovski-Almeida S., et al. Gene expression arrays in cancer research: methods and applications. Crit Rev Oncol Hematol 54 (2005) 95-105
123. Tumor Analysis Best Practices Working Group. Expression profiling-best practices for data generation and interpretation in clinical trials. Nat Rev Genet 5 (2004) 229-237
124. Welsh J.B., Zarrinkar P.P., Sapinoso L.M., et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 98 (2001) 1176-1181
125. Schwartz D.R., Kardia S.L., Shedden K.A., et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62 (2002) 4722-4729
126. Schaner M.E., Ross D.T., Ciaravino G., et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 14 (2003) 4376-4386
127. De Cecco L., Marchionni L., Gariboldi M., et al. Gene expression profiling of advanced ovarian cancer: characterization of molecular signature involving the fibroblast growth factor 2. Oncogene 23 (2004) 8171-8183
128. Donninger H., Bonome T., Radonovich M., et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 23 (2004) 8065-8077
129. Jazaeri A.A., Yee C.J., Sotiriou C., et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 94 (2002) 990-1000
130. Zorn K.K., Jazaeri A.A., Awtrey C.S., et al. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res 9 (2003) 4811-4818
131. Simon R., Radmacher M.D., Dobbin K., and McShane L.M. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95 (2003) 14-18
132. Lee B.C., Cha K., Avraham S., and Avraham H.K. Microarray analysis of differentially expressed genes associated with human ovarian cancer. Int J Oncol 24 (2004) 847-851
133. Hibbs K., Skubitz K.M., Pambuccian S.E., et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 165 (2004) 397-414
134. Lu K.H., Patterson A.P., Wang L., et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10 (2004) 3291-3300
135. Lancaster J.M., Dressman H.K., Whitaker R.S., et al. Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 11 (2004) 51-59
136. Ouellet V., Provencher D.M., Maugard C.M., et al. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 24 (2005) 4672-4687
137. Meinhold-Heerlein I., Bauerschlag D., Hilpert F., et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24 (2005) 1053-1065
138. Ferguson S.E., Olshen A.B., Viale A., Barakat R.R., and Boyd J. Stratification of intermediate-risk endometrial cancer patients into groups at high risk or low risk for recurrence based on tumor gene expression profiles. Clin Cancer Res 11 (2005) 2252-2257
139. Collins Y., Tan D.F., Pejovic T., et al. Identification of differentially expressed genes in clinically distinct groups of serous ovarian carcinomas using cDNA microarray. Int J Mol Med 14 (2004) 43-53
140. Spentzos D., Levine D.A., Ramoni M.F., et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22 (2004) 4700-4710
141. Hartmann L.C., Lu K.H., Linette G.P., et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11 (2005) 2149-2155
142. Berchuck A., Iversen E.S., Lancaster J.M., et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 11 (2005) 3686-3696
143. Spentzos D., Levine D.A., Kolia S., et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 23 (2005) 7911-7918
144. Glinsky G.V., Berezovska O., and Glinskii A.B. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115 (2005) 1503-1521
145. Gygi S.P., Corthals G.L., Zhang Y., Rochon Y., and Aebersold R. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci USA 97 (2000) 9390-9395
146. Zhou G., Li H., DeCamp D., et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 1 (2002) 117-124
147. Hanash S.M. Biomedical applications of two-dimensional electrophoresis using immobilized pH gradients: current status. Electrophoresis 21 (2000) 1202-1209
148. Pappin D.J., Hojrup P., and Bleasby A.J. Rapid identification of proteins by peptide-mass fingerprinting. Curr Biol 3 (1993) 327-332
149. Aebersold R., and Mann M. Mass spectrometry-based proteomics. Nature 422 (2003) 198-207
150. Stone K.L., DeAngelis R., LoPresti M., et al. Use of liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) for routine identification of enzymatically digested proteins separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Electrophoresis 19 (1998) 1046-1052
151. Alaiya A.A., Franzén B., Fujioka K., et al. Phenotypic analysis of ovarian carcinoma: polypeptide expression in benign, borderline and malignant tumors. Int J Cancer 73 (1997) 678-683
152. Alaiya A.A., Franzen B., Hagman A., et al. Classification of human ovarian tumors using multivariate data analysis of polypeptide expression patterns. Int J Cancer 86 (2000) 731-736
153. He Q.Y., Zhou Y., Wong E., et al. Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies. Gynecol Oncol 98 (2005) 68-76
154. Jones M.B., Krutzsch H., Shu H., et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2 (2002) 76-84
155. Ott H.W., Lindner H., Sarg B., et al. Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res 63 (2003) 7507-7514
156. Ahmed N., Barker G., Oliva K.T., et al. Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer 91 (2004) 129-140
157. Ye B., Cramer D.W., Skates S.J., et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 9 (2003) 2904-2911
158. Seibert V., Wiesner A., Buschmann T., and Meuer J. Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research. Pathol Res Pract 200 (2004) 83-94
159. Wulfkuhle J.D., McLean K.C., Paweletz C.P., et al. New approaches to proteomic analysis of breast cancer. Proteomics 1 (2001) 1205-1215
160. Davies H., Lomas L., and Austen B. Profiling of amyloid beta peptide variants using SELDI Protein Chip arrays. Biotechniques 27 (1999) 1258-1261
161. Petricoin E.F., Ardekani A.M., Hitt B.A., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
162. Zhang Z., Bast Jr. R.C., Yu Y., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64 (2004) 5882-5890
163. Carninci P., Kasukawa T., Katayama S., et al. The transcriptional landscape of the mammalian genome. Science 309 (2005) 1559-1563
164. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004) 281-297
165. Bartel D.P., and Chen C.Z. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 5 (2004) 396-400
166. Takamizawa J., Konishi H., Yanagisawa K., et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64 (2004) 3753-3756
167. Chan J.A., Krichevsky A.M., and Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65 (2005) 6029-6033
168. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 435 (2005) 834-838
169. Fan T.W., Lane A.N., and Higashi R.M. The promise of metabolomics in cancer molecular therapeutics. Curr Opin Mol Ther 6 (2004) 584-592
170. Dunn W.B., Bailey N.J., and Johnson H.E. Measuring the metabolome: current analytical technologies. Analyst 130 (2005) 606-625
171. Odunsi K., Wollman R.M., Ambrosone C.B., et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer 113 (2005) 782-788
172. Iorio E., Mezzanzanica D., Alberti P., et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 65 (2005) 9369-9376
173. Ransohoff D.F. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4 (2004) 309-314
174. Feinstein A. Multivariable analysis: an introduction (1996), Yale Univesity Press, New Haven
175. Sayer R.A., Lancaster J.M., Pittman J., et al. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol 96 (2005) 355-361
176. Brenton J.D., Carey L.A., Ahmed A.A., and Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol 23 (2005) 7350-7360
177. Miller L.D., Smeds J., George J., et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102 (2005) 13550-13555
178. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23 (2005) 7332-7341
179. Ransohoff D.F. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 5 (2005) 142-149
180. McShane L.M., Altman D.G., and Sauerbrei W. Identification of clinically useful cancer prognostic factors: what are we missing?. J Natl Cancer Inst 97 (2005) 1023-1025
181. Maihle N.J., Baron A.T., Barrette B.A., et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res 107 (2002) 247-258
182. Levine D.A., Bogomolniy F., Yee C.J., et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11 (2005) 2875-2878
183. Plisiecka-Halasa J., Karpinska G., Szymanska T., et al. P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens. Ann Oncol 14 (2003) 1078-1085
184. Rosen D.G., Wang L., Atkinson J.N., et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99 (2005) 267-277
185. Dinulescu D.M., Ince T.A., Quade B.J., et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11 (2005) 63-70
186. Rosen D.G., Wang L., Jain A.N., et al. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res 10 (2004) 6559-6566
187. Bagnoli M., Tomassetti A., Figini M., et al. Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to a-folate receptor overexpression. Oncogene 19 (2000) 4754-4763
188. Raspollini M.R., Castiglione F., Degl'Innocenti D.R., et al. Bcl-2 in ovarian carcinoma: a clinicopathologic, immunohistochemical and molecular study. Pathologica 96 (2004) 465-469
189. Kupryjanczyk J., Szymanska T., Madry R., et al. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer 88 (2003) 848-854
190. Mezzanzanica D., Balladore E., Turatti F., et al. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin Cancer Res 10 (2004) 5202-5214
191. Cunat S., Hoffmann P., and Pujol P. Estrogens and epithelial ovarian cancer. Gynecol Oncol 94 (2004) 25-32
192. Bali A., O'Brien P.M., Edwards L.S., et al. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 10 (2004) 5168-5177
193. Manenti L., Riccardi E., Marchini S., et al. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther 4 (2005) 715-725
194. Sundfeldt K., Piontkewitz Y., Ivarsson K., et al. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer 74 (1997) 275-280
195. Miotti S., Tomassetti A., Facetti I., et al. Simultaneous expression of caveolin-1 and e-cadherin in ovarian carcinoma cells stabilizes adherens junctions through inhibition of src-related kinases. Am J Pathol 167 (2005) 1411-1427
196. Wong A.S., Roskelley C.D., Pelech S., et al. Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. Exp Cell Res 299 (2004) 248-256
197. Demeter A., Sziller I., Csapo Z., et al. Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer. Anticancer Res 25 (2005) 2885-2889
198. Davidson B., Goldberg I., Berner A., et al. Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions. Am J Clin Pathol 115 (2001) 517-524
199. Rosano L., Varmi M., Salani D., et al. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 61 (2001) 8340-8346
200. Springett G.M., Bonham L., Hummer A., et al. Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies. Cancer Res 65 (2005) 9415-9425
201. Wang Y., Helland A., Holm R., et al. TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br J Cancer 90 (2004) 678-685
202. Havrilesky L., Darcy M., Hamdan H., et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 21 (2003) 3814-3825
203. Smith-Sorensen B., Kaern J., Holm R., et al. Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer 78 (1998) 375-381
204. Niwa K., Itoh M., Murase T., et al. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer 70 (1994) 1191-1197
205. Lakhani S.R., Manek S., Penault-Llorca F., et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 10 (2004) 2473-2481
206. Pharoah P.D., Easton D.F., Stockton D.L., Gayther S., and Ponder B.A. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res 59 (1999) 868-871
207. Johannsson O.T., Ranstam J., Borg A., and Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 16 (1998) 397-404
208. Aida H., Takakuwa K., Nagata H., et al. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 4 (1998) 235-240
209. Tenti P., Vesentini N., Rondo S.M., et al. p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from northern Italy. Cancer Epidemiol Biomarkers Prev 9 (2000) 435-438
210. Lattuada D., Vigano P., Somigliana E., et al. Analysis of the codon 72 polymorphism of the TP53 gene in patients with endometriosis. Mol Hum Reprod 10 (2004) 651-654
211. Fedor H.L., and De Marzo A.M. Practical methods for tissue microarray construction. Meth Mol Med 103 (2005) 89-101
212. Manley S., Mucci N.R., De Marzo A.M., and Rubin M.A. Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model. Am J Pathol 159 (2001) 837-843
213. Ding C., and Cantor C.R. Quantitative analysis of nucleic acids-the last few years of progress. J Biochem Mol Biol 37 (2004) 1-10
214. Posadas E.M., Simpkins F., Liotta L.A., MacDonald C., and Kohn E.C. Proteomic analysis for the early detection and rational treatment of cancer-realistic hope?. Ann Oncol 16 (2005) 16-22